查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968446

傷口敷料市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、最終用途、地區和競爭對手分類，2021-2031年

Topical Wound Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球外用傷口護理產品市場預計將從 2025 年的 19.7 億美元成長到 2031 年的 31.2 億美元，複合年成長率為 7.96%。

這些藥物是專門配製的，直接應用於皮膚傷口，旨在促進癒合、預防感染和控制滲出液。該市場的成長主要受全球慢性疾病（例如糖尿病）盛行率上升的驅動，這些疾病顯著增加了患者發生難癒合性潰瘍的風險。根據國際糖尿病聯盟 (IDF) 預測，到 2024 年，全球將有約 5.89 億成年人患有糖尿病，這將持續推動對有效創傷護理解決方案的需求。此外，人口老化也促進了市場擴張，因為與老齡化相關的生理變化會延緩傷口縫合，因此需要更長的治療通訊協定。

市場概覽
預測期 2027-2031
市場規模：2025年 19.7億美元
市場規模：2031年 31.2億美元
複合年成長率：2026-2031年 7.96%
成長最快的細分市場 奶油
最大的市場 北美洲

然而，由於抗生素抗藥性威脅日益加劇，市場面臨許多重大挑戰。抗藥性菌株的增加降低了標準外用抗生素的療效，使治療方案複雜化，並對臨床結果產生負面影響。這項挑戰迫使監管機構實施更嚴格的核准指南，導致製造商的研發成本增加，研發週期延長。因此，開發符合不斷變化的合理抗生素使用標準的創新療法仍然是阻礙市場整體成長的一大障礙。

市場促進因素

需要術後傷口管理的外科手術數量不斷增加，是推動市場擴張的主要因素。從整形外科置換術到美容整形手術都會產生急性傷口。專業的局部護理對於確保傷口縫合、控制滲出液和最大限度減少手術部位感染（SSI）至關重要。隨著全球手術數量的成長，旨在最佳化癒合和降低再入院率的先進敷料、密封劑和負壓傷口治療（NPWT）設備的消耗量也在增加。國際美容整形外科學會（ISAPS）在2025年6月發布的報告也印證了這一趨勢：2024年全球手術量將超過1740萬例，這凸顯了需要有效術後創傷護理解決方案的患者群體顯著擴大。

生物活性和抗菌外用製劑的技術進步，透過滿足慢性及難治性傷口的複雜需求，進一步推動了市場成長。細胞和組織衍生產品、含銀敷料以及生物膜破壞劑等創新技術，因其能夠更有效地調節傷口環境並對抗抗生素抗藥性，正逐步取代傳統的被動治療方法。這種向高效、高品質產品的轉變，不僅提高了製造商的獲利能力，也改善了抗生素抗藥性感染疾病患者的治療效果。例如，史密斯醫療（Smith & Nephew）公司報告稱，其生物活性傷口護理產品在2025年2月的核心收入成長了20.3%；同年4月，莫爾尼克醫療（Molnlycke Healthcare）宣布其年銷售額達到20.64億歐元。這些都顯示，全球對創新創傷護理技術的需求十分旺盛。

市場挑戰

抗生素抗藥性的日益嚴重對全球外用傷口護理產品市場構成重大挑戰。隨著細菌對標準療法產生抗藥性，現有局部抗生素的臨床效用下降，迫使醫療機構限制其使用以維持有效性。這場抗藥性危機導致監管機構實施了嚴格的核准要求，並要求進行複雜且高成本的臨床試驗，以證明其優於現有標準。因此，製造商面臨更高的研發成本和更長的開發週期，顯著降低了新型創傷護理配方的投資報酬率。

研發能夠有效中和抗藥性菌株並嚴格遵守控制通訊協定的新型化合物，其科學難度之大，加劇了這項挑戰。目前的開發平臺中，創新缺口顯而易見。根據國際藥品製造商協會聯合會（IFPMA）統計，在2024年被列為高優先級的四種針對細菌病原體的候選抗生素中，僅有一種進入了III期臨床試驗。後期候選藥物的匱乏凸顯了企業在將新型高效能外用製劑推向市場方面面臨的嚴峻挑戰，直接限制了產業發展。

市場趨勢

奈米技術的應用正在革新局部製劑領域，它能夠開發出先進的遞送系統，從而提高抗菌和創傷治療化合物的治療指數。與傳統製劑不同，脂質奈米顆粒和金屬奈米複合材料等奈米載體能夠更有效地滲透到複雜的傷口組織和緻密的細菌生物膜中，使活性成分能夠持續釋放到感染部位。這種精準性顯著加速了慢性潰瘍的組織修復機制，同時降低了全身毒性的風險。作為其有效性的證據，聖保羅州研究基金會（FAPESP）於2025年3月重點報導的一項研究表明，可再生，一種新開發的銀奈米顆粒浸漬纖維素敷料在複雜皮膚損傷中實現了超過97%的平均傷口收縮率。

同時，在嚴格的抗菌藥物使用規範和多重抗藥性病原體危機日益嚴峻的推動下，市場正經歷著從傳統局部抗生素到非抗生素抗菌劑的重大轉變。製造商正優先開發利用離子化銀、界面活性劑和抗菌肽等替代抗菌劑的敷料和藥物，這些抗菌劑能夠有效去活化病原體且不會誘導抗藥性。隨著醫療機構尋求永續的感染控制解決方案，這項策略轉變不僅滿足了監管要求，也顯著提升了該領域的收入。例如，康維特集團（ConvaTec Group）報告稱，其創傷護理業務在2025年2月實現了7.4%的有機收入成長，這主要得益於市場對含銀非抗生素抗菌敷料（如Aquacel Ag+Extra）的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球傷口敷料市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（乳霜、凝膠、噴霧、其他）
    • 按應用（慢性傷口、急性傷口）
    • 依最終用途（醫院、診所、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美傷口敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲傷口敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區傷口敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲傷口敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲傷口敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球傷口敷料市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Smith+Nephew Plc
  • MOlnlycke Health Care AB
  • Teva Pharmaceutical Industries Ltd.
  • Arch Therapeutics, Inc.
  • Viatris Inc.
  • Ipca Laboratories Ltd.
  • CHIESI USA, Inc.
  • Altrazeal Life Sciences Inc.
  • Inotec AMD Ltd.
  • The Wound Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27443

The Global Topical Wound Agents Market is projected to expand from USD 1.97 Billion in 2025 to USD 3.12 Billion by 2031, reflecting a compound annual growth rate of 7.96%. These agents are specialized formulations applied directly to skin injuries to promote healing, prevent infection, and manage exudate. The market is largely driven by the rising global burden of chronic conditions such as diabetes, which significantly increases patient susceptibility to non-healing ulcers. According to the International Diabetes Federation, approximately 589 million adults were living with diabetes globally in 2024, creating a sustained demand for effective wound care solutions. Additionally, the growing geriatric population contributes to market expansion, as age-related physiological changes slow wound closure, necessitating extended treatment protocols.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.97 Billion
Market Size 2031USD 3.12 Billion
CAGR 2026-20317.96%
Fastest Growing SegmentCreams
Largest MarketNorth America

However, the market encounters a major obstacle due to the escalating threat of antimicrobial resistance. The rise of resistant bacterial strains reduces the effectiveness of standard topical antibiotics, complicating treatment plans and negatively impacting clinical outcomes. This challenge compels regulatory authorities to enforce stricter approval guidelines, which subsequently increases development costs and extends timelines for manufacturers. Consequently, the difficulty in developing novel therapeutics that align with evolving antibiotic stewardship standards remains a critical barrier that could hinder broader market growth.

Market Driver

The increasing volume of surgical procedures requiring post-operative wound management acts as a primary catalyst for market expansion. Surgical interventions, ranging from orthopedic replacements to aesthetic reconstructions, inherently create acute wounds that demand specialized topical care to ensure proper closure, control exudate, and minimize surgical site infections (SSIs). As the number of operations rises globally, so does the consumption of advanced dressings, sealants, and negative pressure wound therapy devices designed to optimize healing and reduce hospital readmissions. Highlighting this trend, the International Society of Aesthetic Plastic Surgery (ISAPS) reported in June 2025 that over 17.4 million surgical procedures were performed worldwide in 2024, emphasizing the substantial and growing patient pool requiring effective post-surgical wound care solutions.

Technological advancements in bioactive and antimicrobial topical formulations are further driving market growth by addressing the complex needs of chronic and hard-to-heal wounds. Innovations such as cellular and tissue-based products, silver-impregnated dressings, and biofilm-disrupting agents are increasingly replacing traditional passive therapies due to their superior ability to modulate the wound environment and combat antimicrobial resistance. This shift toward high-efficacy, premium products is boosting manufacturer revenues and improving outcomes for patients with resistant infections. For instance, Smith & Nephew reported in February 2025 that their Advanced Wound Bioactives segment achieved 20.3% underlying revenue growth, while Molnlycke Health Care announced annual sales of EUR 2,064 million in April 2025, underscoring the robust global demand for innovative wound care technologies.

Market Challenge

The rising threat of antimicrobial resistance presents a formidable barrier to the Global Topical Wound Agents Market. As bacteria evolve to withstand standard treatments, the clinical utility of existing topical antibiotics diminishes, forcing healthcare providers to restrict their usage to preserve efficacy. This resistance crisis drives regulatory agencies to enforce stringent approval requirements, necessitating complex and expensive clinical trials to demonstrate superiority over current standards. Consequently, manufacturers face escalated research and development costs alongside prolonged timelines, which significantly reduces the return on investment for new wound care formulations.

This challenge is further exacerbated by the scientific difficulty in discovering novel compounds that can effectively neutralize resistant strains while complying with rigorous stewardship protocols. This innovation gap is evident in the current development pipeline. According to the International Federation of Pharmaceutical Manufacturers and Associations, there was only one antibiotic candidate in Phase III clinical trials targeting the four bacterial pathogens classified as critical priorities in 2024. This scarcity of late-stage candidates highlights the profound obstacles companies face in bringing new, effective topical agents to market, directly constraining sector growth.

Market Trends

The application of nanotechnology is revolutionizing the topical agents sector by enabling the development of advanced delivery systems that enhance the therapeutic index of antimicrobial and healing compounds. Unlike traditional formulations, nanocarriers such as lipid nanoparticles and metal nanocomposites offer superior penetration into complex wound topographies and dense bacterial biofilms, ensuring sustained release of active ingredients directly at the infection site. This precision reduces systemic toxicity risks while significantly accelerating tissue repair mechanisms in chronic ulcers. Validating this efficacy, Agencia FAPESP highlighted a study in March 2025 where a novel silver nanoparticle-impregnated cellulose dressing achieved an average wound contraction rate of more than 97% in complex skin lesions, demonstrating the potent regenerative potential of these nanoscale interventions.

Concurrently, there is a decisive market shift away from conventional topical antibiotics toward non-antibiotic antimicrobial formulations, driven by stringent antibiotic stewardship programs and the escalating crisis of multidrug-resistant pathogens. Manufacturers are increasingly prioritizing the commercialization of dressings and agents utilizing alternative biocides, such as ionic silver, surfactants, and antimicrobial peptides, which effectively neutralize pathogens without inducing resistance. This strategic pivot meets regulatory demands and drives substantial segment revenue as healthcare providers seek durable infection control solutions. For example, Convatec Group Plc reported in February 2025 that its Advanced Wound Care business recorded 7.4% organic revenue growth, a performance primarily attributed to the robust demand for its silver-containing, non-antibiotic antimicrobial dressings like Aquacel Ag+ Extra.

Key Market Players

  • Smith+Nephew Plc
  • MOlnlycke Health Care AB
  • Teva Pharmaceutical Industries Ltd.
  • Arch Therapeutics, Inc.
  • Viatris Inc.
  • Ipca Laboratories Ltd.
  • CHIESI USA, Inc.
  • Altrazeal Life Sciences Inc.
  • Inotec AMD Ltd.
  • The Wound Company

Report Scope

In this report, the Global Topical Wound Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Topical Wound Agents Market, By Product

  • Creams
  • Gels
  • Sprays
  • Others

Topical Wound Agents Market, By Application

  • Chronic Wounds
  • Acute Wounds

Topical Wound Agents Market, By End Use

  • Hospitals
  • Clinics
  • Others

Topical Wound Agents Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Topical Wound Agents Market.

Available Customizations:

Global Topical Wound Agents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Topical Wound Agents Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Creams, Gels, Sprays, Others)
    • 5.2.2. By Application (Chronic Wounds, Acute Wounds)
    • 5.2.3. By End Use (Hospitals, Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Topical Wound Agents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Topical Wound Agents Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End Use
    • 6.3.2. Canada Topical Wound Agents Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End Use
    • 6.3.3. Mexico Topical Wound Agents Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End Use

7. Europe Topical Wound Agents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Topical Wound Agents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End Use
    • 7.3.2. France Topical Wound Agents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Topical Wound Agents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Topical Wound Agents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Topical Wound Agents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End Use

8. Asia Pacific Topical Wound Agents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Topical Wound Agents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Topical Wound Agents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End Use
    • 8.3.3. Japan Topical Wound Agents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End Use
    • 8.3.4. South Korea Topical Wound Agents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Topical Wound Agents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End Use

9. Middle East & Africa Topical Wound Agents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Topical Wound Agents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End Use
    • 9.3.2. UAE Topical Wound Agents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End Use
    • 9.3.3. South Africa Topical Wound Agents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End Use

10. South America Topical Wound Agents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Topical Wound Agents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End Use
    • 10.3.2. Colombia Topical Wound Agents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End Use
    • 10.3.3. Argentina Topical Wound Agents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Topical Wound Agents Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Smith+Nephew Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. MOlnlycke Health Care AB
  • 15.3. Teva Pharmaceutical Industries Ltd.
  • 15.4. Arch Therapeutics, Inc.
  • 15.5. Viatris Inc.
  • 15.6. Ipca Laboratories Ltd.
  • 15.7. CHIESI USA, Inc.
  • 15.8. Altrazeal Life Sciences Inc.
  • 15.9. Inotec AMD Ltd.
  • 15.10. The Wound Company

16. Strategic Recommendations

17. About Us & Disclaimer